Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
PR Newswire —
First Investigational Gene Therapy for Pitt Hopkins Syndrome Intended to Address Underlying Disease Biology SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 /PRNewswire/ -- Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders,...